Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

BACKGROUND: Tumor mutational burden (TMB) is a significant predictor of immune checkpoint inhibitors (ICIs) efficacy. This study investigated the correlation between deep learning radiomic biomarker and TMB, including its predictive value for ICIs treatment response in patients with advanced non-sma...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: He, Bingxi, Dong, Di, She, Yunlang, Zhou, Caicun, Fang, Mengjie, Zhu, Yongbei, Zhang, Henghui, Huang, Zhipei, Jiang, Tao, Tian, Jie, Chen, Chang
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Immunotherapy Biomarkers
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7342823/
https://ncbi.nlm.nih.gov/pubmed/32636239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000550
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi